Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
March 2015
-
Media Release
Novartis announces completion of transactions with GSK
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus… -
Media Release
Novartis gibt Abschluss von Transaktionen mit GSK bekannt
Mit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe… -
Media Release
Novartis annonce la conclusion des transactions avec GSK
Conclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
February 2015
-
Media Release
Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration
Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less… -
Media Release
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Shareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur… -
Media Release
Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis
Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des… -
Media Release
Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib
If approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the… -
Story Patient Perspectives
Why research into rare diseases matters
Hundreds of millions of people worldwide await treatments for rare diseases.
-
Story From Our Labs
Chemical genetics: The sleuthing behind modern drug discovery
Researchers at Novartis are combining modern techniques with an old approach to drug discovery and getting surprising results.
-
Media Release
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median… -
Story Discovery
Researchers aim to beat trick play by tumors with drug combo